Abstract
A remarkable acceleration in the development of vaccines was witnessed during the Covid-19 pandemic. However, progress along the vaccine research and development continuum must continue, particularly in the context of epidemic preparedness and response. In this review, we explore recent innovations that have advanced vaccinology, particularly in the development of antigens and vaccine platforms, as well as clinical evidence strategies that accelerate the evaluation of vaccine candidates, adapted to an epidemic setting. We discuss the challenges of international collaboration, notably in the European context, and accessibility to vaccines for low- and middle-income countries. This analysis leads us to the conclusion that technological innovation and global collaboration must be developed simultaneously and in synergy to improve our response to the next epidemic.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
